Siberian Heatwave Sparks Anthrax Outbreak, Killing A Child And Thousands Of Reindeer
At least one child has died in Siberia after an outbreak of naturally occurring anthrax, which has been linked to a decades-old reindeer carcass exposed during a heatwave.
Russian officials have said the death of a 12-year-old boy, a member of a reindeer-herding family from the Yamal tundra 1,300 miles north of Moscow, was the first fatality in Siberia linked to the pathogen since 1941. Twenty others have been diagnosed with anthrax, according to CBS.
The region’s governor, Dmitry Kobylkin, linked the outbreak to a massive temperature spike in the region that has melted the permafrost ― a thick layer of soil a...
Source: Healthy Living - The Huffington Post - August 2, 2016 Category: Consumer Health News Source Type: news
Anthrax Vaccine Shows Promise in Monkey Trial
FRIDAY, July 1, 2016 -- A vaccine made with a component of the bacteria that causes anthrax protected monkeys from the deadly infection in a preliminary trial.
Previous research showed that this component -- the anthrax capsule -- played a pivotal... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 1, 2016 Category: Journals (General) Source Type: news
Anthrax capsule vaccine completely protects monkeys from lethal inhalational anthrax
Vaccination with the anthrax capsule -- a naturally occurring component of the bacterium that causes the disease -- completely protected monkeys from lethal anthrax infection, according to a study. These results indicate that anthrax capsule is a highly effective vaccine component that should be considered for incorporation in future generation anthrax vaccines. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 27, 2016 Category: Science Source Type: news
Anthrax capsule vaccine completely protects monkeys from lethal inhalational anthrax
(US Army Medical Research Institute of Infectious Diseases) Vaccination with the anthrax capsule -- a naturally occurring component of the bacterium that causes the disease -- completely protected monkeys from lethal anthrax infection, according to a study published online this week in the journal VACCINE. These results indicate that anthrax capsule is a highly effective vaccine component that should be considered for incorporation in future generation anthrax vaccines. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 27, 2016 Category: Infectious Diseases Source Type: news
Nigeria: Anthrax - Kaduna Procures 150,000 Doses of Vaccines
[Daily Trust] Kaduna -Kaduna State Commissioner for Agriculture and Forestry, Dr. Manzo Maigari has said that there is no case of anthrax in the state,saying 150,000 doses of vaccines have been procured as a preventive measure. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 3, 2016 Category: African Health Source Type: news
Development of a Solid Dose Injection Recombinant Anthrax Vaccine
Glide Technologies is a UK development company focused on solid dose formulations of therapeutics and vaccines, and non-invasive diagnostics. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2016 Category: Pharmaceuticals Source Type: news
Solid Formulation of a Recombinant Anthrax Vaccine
Pfenex and Glide Pharma have an ongoing collaboration to develop an anthrax vaccine containing the recombinant protective antigen (rPA) from Bacillus anthracis produced using Pfēnex expression technology, which is suitable for delivery with the Glide… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2016 Category: Pharmaceuticals Source Type: news
FDA Expands Use of Anthrax Vaccine to Include Postexposure Prevention (FREE)
By Kristin J. Kelley
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The only FDA-licensed anthrax vaccine, marketed as BioThrax, is … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 25, 2015 Category: Primary Care Source Type: news
Anthrax Vaccine Approved for Postexposure ProtectionAnthrax Vaccine Approved for Postexposure Protection
Studies indicate that people receiving BioThrax after a confirmed or suspected exposure to the bacterium that causes the disease may have a 70% chance of surviving. FDA Approvals (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - November 24, 2015 Category: Emergency Medicine Tags: Infectious Diseases News Alert Source Type: news
Anthrax Vaccine Approval Expanded
Now sanctioned for adults 18 to 65 with known or suspected exposure
Source: HealthDay
Related MedlinePlus Page: Anthrax (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 24, 2015 Category: Consumer Health News Source Type: news
FDA approves expanded use of Emergent BioSolution's anthrax vaccine
(Reuters) - The U.S. Food and Drug Administration approved to expand the use of Emergent BioSolutions Inc's anthrax vaccine to prevent suspected or confirmed exposure to the bacterium that causes the disease. (Source: Reuters: Health)
Source: Reuters: Health - November 23, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves vaccine for use after known or suspected anthrax exposure
The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine’s new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 23, 2015 Category: American Health Source Type: news
Development of New Anthrax Vaccine Underway With HHS Support
A new anthrax vaccine that could be easier and faster to produce than the existing licensed product will undergo initial clinical studies through an agreement between the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and Pfenex, Inc. of San Diego. (Source: PHPartners.org)
Source: PHPartners.org - November 9, 2015 Category: Global & Universal Source Type: news
FDA and access to medical countermeasures during public health emergencies
By: Brooke Courtney, J.D., M.P.H.
Just weeks after witnessing the fall of the World Trade Center on Sept. 11, 2001, I was a student volunteer in a New York City hospital emergency department when several people arrived saying they had been exposed to anthrax.
One had even brought a small plastic bag holding white powder. Around this time, the media was reporting on letters mailed that were laced with white powder confirmed to be Bacillus anthracis, which causes anthrax.
At the hospital, we wondered whether we might become exposed to anthrax and how it could be prevented or treated. We quickly escorted the patients who had ...
Source: Mass Device - October 13, 2015 Category: Medical Equipment Authors: MassDevice Tags: Blog FDA Source Type: news
Development of New Anthrax Vaccine Underway With HHS Support
A new anthrax vaccine that could be easier and faster to produce than the existing licensed product will undergo initial clinical studies through an agreement between the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and Pfenex, Inc. of San Diego. (Source: PHPartners.org)
Source: PHPartners.org - August 27, 2015 Category: Global & Universal Source Type: news
